Back to discover
Disease

Simian Acquired Immunodeficiency Syndrome

Late-stage therapeutic developmentEmerging research
MeSHSimian Acquired Immunodeficiency Syndrome
2
Publications
24
Clinical trials
2024
Latest publication
Current focus
Therapeutic developmentGenetics & risk factorsInflammation & immunityMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q2 2029.
Upcoming Milestones
Clinical Milestones7View
Results expected 2
Recently completed 1
Other updates 4
Activity timeline7

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net -4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Implementation for Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Using Novel Regimen of Isoniazid/Rifapentine Daily (4 Weeks) Compared to Isoniazid/Rifapentine Weekly (12 Weeks)

Phase 3 · Active, not recruiting · The HIV Netherlands Australia Thailand Research Collaboration

A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Phase 2/3 · Active, not recruiting · Gilead Sciences

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed

Phase 3 · Active, not recruiting · ViiV Healthcare

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Phase 3 · Active, not recruiting · Gilead Sciences

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC
Recently completed

Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone

Phase 4 · Completed · Boehringer Ingelheim

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets

Phase 4 · Completed · Boehringer Ingelheim

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

Phase 3 · Completed · Pharmacia

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

Phase 3 · Completed · SmithKline Beecham

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2023–2024
Recent publications

From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy.

Microbiome · 2024 · 13 cites

How to Build a Fire: The Genetics of Autoinflammatory Diseases.

Annual review of genetics · 2023 · 14 cites
Major themes8
  • Simian Acquired Immunodeficiency Syndrome2
  • Dysbiosis1
  • Fecal Microbiota Transplantation1
  • Gastrointestinal Microbiome1
  • Hereditary Autoinflammatory Diseases1
  • HIV Infections1
  • Probiotics1
  • Simian immunodeficiency virus1
Leading journals2
  • Annual review of genetics1
  • Microbiome1
Leading researchers6
  • Aksentijevich I1
  • Brenchley JM1
  • Lee PY1
  • Serrano-Villar S1
  • Zhang J1
  • Zhou Q1
Affiliations (unnormalised)5
  • Boston Children's Hospital1
  • Hospital Universitario Ramon y Cajal1
  • Liangzhu Laboratory1
  • Life Sciences Institute1
  • National Human Genome Research Institute1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.

Identifiers
MeSHSimian Acquired Immunodeficiency Syndrome
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.